FrancophonIA/ELRC3.0 huggingface dataset:
English: Ultratard doses might also need to be adjusted when given with a number of other medicines which may have an effect on blood sugar (the full list is available in the Package Leaflet).
Estonian: Samuti võib osutuda vajalikuks kohandada Ultratardi annust, kui seda võetakse koos mõne teise ravimiga, mis võib mõjutada veresuhkru taset (ravimite täielik loetelu on pakendi infolehel).
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate oma haigusseisundi või ravi osas asjakohast lisateavet, lugege palun pakendi infolehte (mis on samuti ravimi Euroopa avaliku hindamisaruande osa) või võtke ühendust oma arsti või apteekriga.
English: The Committee for Medicinal products for Human Use (CHMP) decided that Ultratard's benefits are greater than its risks for the treatment of diabetes.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et Ultratardi kasulikkus suhkurtõve ravis on suurem kui sellega kaasnevad riskid.
English: Other information about Ultratard:
Estonian: Muu teave Ultratardi kohta
English: Diabetes is a disease in which the body does not produce enough insulin to control the blood sugar.
Estonian: Suhkurtõbi on haigus, mille puhul organism ei tooda veresuhkru reguleerimiseks piisavalt insuliini.
English: What is the risk associated with Ultratard?
Estonian: Millised on Ultratardiga kaasnevad riskid?
English: Ultratard can be used in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin effectively.
Estonian: Ultratardi saab kasutada I tüüpi suhkurtõve puhul, kui kõhunääre ei suuda toota insuliini, ja II tüüpi suhkurtõve puhul, kui organism ei suuda insuliini tõhusalt kasutada.
English: Ultratard should not be used in people who may be hypersensitive (allergic) to insulin human (rDNA) or to any of the other ingredients.
Estonian: Ultratardi ei tohi kasutada inimestel, kes võivad olla iniminsuliini (rDNA) või mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: By controlling the blood sugar, the symptoms and complications of diabetes are reduced.
Estonian: Veresuhkru taseme reguleerimisega harvenevad suhkurtõve sümptomid ja tüsistused.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Estonian: Kui soovite lisateavet inimtervishoius kasutatavate ravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti ravimi Euroopa avaliku hindamisaruande osa).
English: Ultratard contains the active ingredient insulin human (rDNA).
Estonian: Ultratard sisaldab toimeainena iniminsuliini (rDNA).
English: The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Asendusinsuliin toimib samal viisil kui loomulikul teel tekkinud insuliin ning ta aitab vereglükoosil siseneda rakkudesse.
English: If convenient it may also be given in the abdominal wall (tummy), the buttocks or the deltoid region (shoulder).
Estonian: Seda võib mugavuse korral süstida ka kõhu, tuharate või deltalihase (õla piirkond) naha alla.
English: Ultratard contains insulin mixed with another substance, zinc, in particles from which the insulin is absorbed much more slowly during the day; and this gives Ultratard a longer duration of action.
Estonian: Ultratard sisaldab teise ainega, tsingiga segatud insuliini, mis moodustab osakesi, millest insuliin imendub päeva kestel palju aeglasemalt ja seepärast on Ultratardi toimeaeg pikem.
English: Ultratard has been studied in both type 1 and type 2 diabetes, and it has been compared to other types of insulin (porcine, human).
Estonian: Ultratardi uuriti nii I kui II tüüpi suhkurtõvega patsientidel ja seda võrreldi muude insuliini liikidega (seainsuliin, iniminsuliin).
English: Ultratard is used in patients with diabetes mellitus.
Estonian: Ultratardi kasutatakse suhkurtõvega patsientidel.
English: Ultratard is a long-acting insulin, it can be given as a once daily or twice daily injection, with or without a fast-acting insulin (at meal times), according to the doctor's recommendation.
Estonian: Seda saab süstida üks või kaks korda päevas, kas koos kiiretoimelise insuliiniga (söögiaegadel) või ilma, toimides vastavalt arsti soovitusele.
English: Why has Ultratard been approved?
Estonian: Miks Ultratard heaks kiideti?
English: Ultratard may cause hypoglycaemia (low blood sugar).
Estonian: Ultratard võib põhjustada hüpoglükeemiat (veresuhkru madalat taset).
English: Ultratard led to a decrease in the level of HbA1c, indicating that blood sugar levels had been controlled to a similar level to that seen with other human insulin.
Estonian: Ultratard vähendas HbA1c sisaldust, mis näitas, et organism reguleeris veresuhkru sisaldust samamoodi kui muu iniminsuliini korral.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ULTRATARD EPAR summary for the public
Estonian: ULTRATARD Kokkuvõte üldsusele
English: Ultratard is given subcutaneously (under the skin) by injection, usually in the thigh.
Estonian: Ultratardi manustatakse subkutaanse (nahaaluse) süstega, tavaliselt reide.
English: Ultratard was effective for both Type 1 and Type 2 diabetes.
Estonian: Ultratard oli tõhus nii I kui II tüüpi suhkurtõve puhul.
English: What is Ultratard?
Estonian: Mis on Ultratard?
English: For the full description of the side effects reported with Ultratard, please see the Package Leaflet.
Estonian: Ultratardi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What benefit has Ultratard shown during the studies?
Estonian: Milles seisneb uuringute põhjal Ultratardi kasulikkus?
English: How has Ultratard been studied?
Estonian: Kuidas Ultratardi uuriti?
English: The insulin is made by a yeast that has received a gene (DNA), which makes it able to produce insulin.
Estonian: Insuliini valmistatakse pärmi alusel, millesse on viidud insuliini teket võimaldav geen (DNA).
English: The full EPAR for Ultratard is available here.
Estonian: Ultratardi Euroopa avaliku hindamisaruande täisteksti leiate siit.
English: How does Ultratard work?
Estonian: Kuidas Ultratard toimib?
English: How is Ultratard used?
Estonian: Kuidas Ultratardi kasutatakse?
English: Ultratard is a replacement insulin which identical to the insulin made by the pancreas .The active ingredient of Ultratard, insulin human (rDNA), is produced by a method known as ‘recombinant technology'.
Estonian: Ultratardi toimeainet iniminsuliini (rDNA) toodetakse rekombinatsioonitehnoloogiaks nimetataval meetodil.
English: Ultratard is an insulin suspension for injection.
Estonian: Ultratard on insuliini süstesuspensioon.
English: What is Ultratard used for?
Estonian: Milleks Ultratardi kasutatakse?
English: The European Commission issued a Decision on 22 September 2011.
Estonian: Euroopa Komisjon tegi otsuse 22. septembril 2011.
English: What is Canazole?
Estonian: Mis on Canazole?
English: The marketing authorisation in Ireland should also be suspended.
Estonian: Ka Iirimaal antud müügiluba tuleb peatada.
English: Why was Canazole reviewed?
Estonian: Miks ravimi Canazole taotlus uuesti üle vaadati?
English: The company which recently marketed this product wanted the authorisation to be recognised in the United Kingdom (the ‘concerned Member State').
Estonian: Ravimi hiljuti turule toonud ettevõte taotles müügiloa tunnustamist Ühendkuningriigis (asjaomases liikmesriigis).
English: In addition, the Committee has also recommended that the marketing authorisation for Canazole in Ireland be suspended until further studies are done.
Estonian: Lisaks soovitas komitee peatada ravimi Canazole müügiluba Iirimaal, kuni tehakse täiendavaid uuringuid.
English: Pinewood Laboratories Ltd submitted Canazole for mutual recognition on the basis of the initial authorisation granted by Ireland on 8 December 2000.
Estonian: Pinewood Laboratories Ltd esitas taotluse ravimi Canazole vastastikuse tunnustamise menetluse teostamiseks esmase müügiloa alusel, mis anti Iirimaal 8. detsembril 2000.
English: However, the Member States were not able to reach an agreement and the Irish medicines regulatory agency referred the matter to the CHMP for arbitration on 25 November 2010.
Estonian: Liikmesriigid ei jõudnud kokkuleppele ja Iirimaa ravimiamet tegi 25. novembril 2010 inimravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: The grounds for the referral were that the United Kingdom did not agree that Canazole cream and Canesten cream are similar enough to have therapeutic equivalence.
Estonian: Esildise tegemise aluseks oli asjaolu, et Ühendkuningriik ei nõustunud väitega, et kreem Canazole ja kreem Canesten on piisavalt sarnased, et pidada neid terapeutiliselt ekvivalentseteks.
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the currently available data were not sufficient to show therapeutic equivalence with the reference medicine and that further data would need to be generated.
Estonian: Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, jõudis inimravimite komitee järeldusele, et olemasolevatest andmetest ei piisa, näitamaks terapeutilist
English: Canazole is a cream that contains the active substance clotrimazole (1%).
Estonian: Canazole on kreem, mille toimeaine on klotrimasool (1%).
English: Questions and answers on Canazole (clotrimazole cream 1%) EMA/837098/2011
Estonian: Teave ravimi Canazole kohta (klotrimasool, 1% kreem) EMA/206825/2011
English: It is used to treat skin infections caused by fungi, such as thrush, ringworm or athlete's foot.
Estonian: Seda kasutatakse nahainfektsioonide raviks, mida põhjustavad seened, nagu soor, naha seenhaigused ja jalaseen.
English: Canazole is a generic medicine based on a ‘reference medicine', Canesten, which is authorised in the United Kingdom.
Estonian: Canazole on geneeriline ravim, mille aluseks on võrdlusravim Canesten, millel on Ühendkuningriigis müügiluba.
English: The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Canazole.
Estonian: Euroopa Ravimiamet (EMA) on lõpetanud vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Canazole heakskiitmises.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Canazole do not outweigh its risks, and the marketing authorisation granted in Ireland cannot be recognised in other Member States of the EU.
Estonian: Euroopa Ravimiameti inimravimite komitee otsustas, et Canazole kasulikkus ei ole suurem kui sellega kaasnevad riskid ja Iirimaal antud müügiluba ei või tunnustada teistes Euroopa Liidu liikmesriikides.
English: It works by preventing the formation of ergosterol, which is an important part of fungal cell walls.
Estonian: See pärsib seente rakumembraani olulise koostisaine ergosterooli moodustumist.
English: The CHMP therefore concluded that the benefits of Canazole do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member State.
Estonian: Seetõttu järeldas inimravimite komitee, et Canazole kasulikkus ei ületa ravimiga kaasnevaid riske ning soovitas asjaomastes liikmesriikides müügiluba mitte anda.
English: The active substance in Canazole, clotrimazole, is an antifungal medicine that belongs to the group called triazoles.
Estonian: Ravimi Canazole toimeaine klotrimasool on seenevastane ravim, mis kuulub triasoolide gruppi.
English: Questions and answers on Canazole (clotrimazole cream
Estonian: Teave ravimi Canazole kohta (klotrimasool, 1% kreem)
English: Ref.: EMEA/528144/2009 EMEA/H/C/535
Estonian: Viide: EMEA/528144/2009 EMEA/H/C/535
English: The marketing authorisation was renewed on 13 October 2009.
Estonian: Müügiluba pikendati 13. oktoobril 2009.
English: Wilzin should be taken on an empty stomach, at least one hour before or two to three hours after meals.
Estonian: Wilzinit tuleb võtta tühja kõhuga vähemalt 1 tund enne või 2-3 tundi pärast sööki.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Wilzin to Orphan Europe SARL on 13 October 2004.
Estonian: Euroopa Komisjon andis Wilzini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Orphan Europe SARL 13. oktoobril 2004.
English: This results in copper building up in the body, first in the liver, then in other organs such as the eye and the brain.
Estonian: Selle tulemusena ladestub vask organismis - esmalt maksas, seejärel teistes elundites, näiteks silmades ja ajus.
English: This causes a variety of effects, including liver disease and damage to the nervous system.
Estonian: See põhjustab mitmesuguseid nähte, sealhulgas maksahaigusi ja närvisüsteemi kahjustusi.
English: The usual dose for adults is 50 mg three times a day.
Estonian: Täiskasvanute tavaline annus on 50 mg kolm korda ööpäevas.
English: It is available as capsules (blue: 25 mg; orange: 50 mg).
Estonian: Ravimit turustatakse kapslitena (sinised 25 mg, oranžid 50 mg).
English: A reduced dose is used in children.
Estonian: Lastel kasutatakse väiksemat annust.
English: Patients who are switching from a ‘chelating agent' (another type of medicine for Wilson's disease) to Wilzin should continue to take the chelating agent for two to three weeks after starting Wilzin, because Wilzin takes some time to start working fully.
Estonian: Patsiendid, kes on läinud üle kelaativalt ainelt (Wilsoni tõve teist tüüpi ravim) Wilzinile, peaksid jätkama kelaativa aine võtmist kahe kuni kolme nädala jooksul pärast Wilzini-ravi alustamist, sest Wilzini täielikuks toimima hakkamiseks kulub teatud aeg.
English: Over time, the amount of copper in the body falls, improving the symptoms of the disease.
Estonian: Aja jooksul vase kogus organismis väheneb, leevendades haiguse sümptomeid.
English: The Committee for Medicinal products for Human Use (CHMP) noted that Wilson's disease is a fatal disease and the other medicines already being used for the disease can have severe side effects.
Estonian: Inimravimite komitee märkis, et Wilsoni tõbi on surmav haigus ja teistel tõve ravis juba kasutatavatel ravimitel võivad olla rasked kõrvalnähud.
English: Because zinc has been used to treat Wilson's disease for many years, the company presented the results of studies from the published literature.
Estonian: Kuna tsinki on Wilsoni tõve ravis kasutatud juba palju aastaid, esitas ettevõte tehtud uuringute tulemused avaldatud kirjandusest.
English: Wilzin zinc EPAR summary for the public
Estonian: Wilzin tsink Kokkuvõte üldsusele
English: Gastric irritation is usually worst with the first morning dose and disappears after the first few days of treatment.
Estonian: Maoärritus on suurim esimese hommikuse annuse korral ja kaob pärast mõnepäevast ravi.
English: What is Wilzin?
Estonian: Mis on Wilzin?
English: The Committee recommended that Wilzin be given marketing authorisation.
Estonian: Komitee soovitas anda Wilzinile müügiloa.
English: Other information about Wilzin:
Estonian: Muu teave Wilzini kohta
English: Wilson's disease is a rare inherited disorder where patients lack an enzyme that is needed to eliminate the copper contained in food from the body.
Estonian: Wilsoni tõbi on haruldane pärilik haigus, mille korral patsiendil puudub toidus sisalduva vase organismist eemaldamiseks vajalik ensüüm.
English: The maximum dose of Wilzin is 50 mg five times a day.
Estonian: Wilzini suurim annus on 50 mg viis korda ööpäevas.
English: Zinc has been used to treat Wilson's disease since 1958.
Estonian: Tsinki on Wilsoni tõve ravis kasutatud alates 1958. aastast.
English: Because the number of patients with Wilson's disease is low, the disease is considered ‘rare', and Wilzin was designated an ‘orphan medicine' (a medicine used in rare diseases) on 31 July 2001.
Estonian: Et Wilsoni tõvega patsientide arv on väike ja see haigus esineb harva, nimetati Wilzin 31. juulil 2001 harvikravimiks.
English: The most common side effects with Wilzin (seen in between 1 and 10 patients in 100) are gastric irritation (irritation of the stomach) and increased blood levels of enzymes (amylase, lipase and alkaline phosphatase).
Estonian: Wilzini kõige sagedamad kõrvalnähud (esinenud ühel kuni kümnel patsiendil sajast) on maoärritus ja ensüümide (amülaasid, lipaasid ja aluselised fosfataasid) sisalduse suurenemine veres.
English: What is the risk associated with Wilzin?
Estonian: Mis riskid Wilziniga kaasnevad?
English: Wilzin should not be used in people who may be hypersensitive (allergic) to zinc or any of the other ingredients.
Estonian: Wilzinit ei tohi kasutada patsiendid, kes võivad olla tsingi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: In total, data to support the use of Wilzin came from 255 patients with Wilson's disease.
Estonian: Wilzini kasutamise toetuseks esitati kokku 255 Wilsoni tõvega patsiendi andmed.
English: Why has Wilzin been approved?
Estonian: Miks Wilzin heaks kiideti?
English: This protein attaches to copper and prevents it being transferred into the blood.
Estonian: Nimetatud valk seondub vasega ja takistab vase kandumist vereringesse.
English: Wilzin is a medicine that contains the active substance zinc.
Estonian: Wilzin on ravim, mis sisaldab toimeainena tsinki.
English: Therefore, the Committee decided that Wilzin's benefits are greater than its risks for the treatment of Wilson's disease.
Estonian: Seetõttu otsustas komitee, et Wilzini kasulikkus Wilsoni tõve ravis on suurem kui sellega kaasnevad riskid.
English: Wilzin is a long-term treatment.
Estonian: Ravi Wilziniga on pikaajaline.
English: Delaying the first dose to mid-morning or taking the dose with a small amount of food containing protein, such as meat, may help.
Estonian: Aidata võib esimese hommikuse annuse manustamine alles keskhommikul või annuse manustamine koos valku (nt liha) sisaldava vähese toidukogusega.
English: Wilzin has been shown to be effective in reducing the absorption of copper and reducing the amount of copper in the body.
Estonian: Wilzin osutus efektiivseks, vähendades vase imendumist ja vase sisaldust organismis.
English: It works by stimulating the body to produce a protein called metallothionein in the cells lining the gut.
Estonian: Selle toime seisneb organismi stimuleerimises tootma metallotioneiiniks nimetatavat valku soole sisepinna rakkudes.
English: The main study involved 148 patients who were treated with Wilzin, but did not compare Wilzin with any other treatments.
Estonian: Põhiuuringus, milles osales 148 Wilzini-ravi saanud patsienti, ei võrreldud Wilzinit muude ravimitega Efektiivsuse põhinäitaja oli see, kas vasesisaldust patsientide veres reguleeriti asjakohaselt.
English: In the main study, 91% of the patients evaluated (91 out of 100) had adequate control of their copper levels within the first year of treatment with Wilzin.
Estonian: Wilziniga ravi esimesel aastal täheldati põhiuuringus 91%-l patsientidest (91 patsiendil 100-st) vasesisalduse piisavat reguleerimist.
English: Wilzin is used to treat Wilson's disease.
Estonian: Wilzinit kasutatakse Wilsoni tõve raviks.
English: For the full list of all side effects reported with Wilzin, see the Package Leaflet.
Estonian: Wilzini kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: How does Wilzin work?
Estonian: Kuidas Wilzin toimib?
English: The active substance in Wilzin is the zinc cation (positively charged zinc), which blocks the absorption of copper from the diet.
Estonian: Wilzini toimeaine on tsingi katioon (positiivne tsingiioon), mis blokeerib toidus sisalduva vase imendumist.
English: The summary of opinion of the Committee for Orphan Medicinal Products for Wilzin is available here.
Estonian: Harvikravimite komitee arvamuse kokkuvõtte Wilzini kohta leiate siit.
English: Wilzin treatment should be started by a doctor who has experience in the treatment of Wilson's disease.
Estonian: Ravi Wilziniga tohib alustada üksnes Wilsoni tõve ravis kogenud arst.
English: The copper is then passed out of the body in the stools.
Estonian: Vask väljub seejärel organismist koos väljaheitega.
English: What benefit has Wilzin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Wilzini kasulikkus?
English: How has Wilzin been studied?
Estonian: Kuidas Wilzinit uuriti?
English: How is Wilzin used?
Estonian: Kuidas Wilzinit kasutatakse?
English: The full EPAR for Wilzin can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Wilzini kohta leiate siit.
English: What is Wilzin used for?
Estonian: Milleks Wilzinit kasutatakse?
English: - Tell your doctor:
Estonian: - Rääkige oma arstile sellest:
English: Risk to the infant cannot be excluded.
Estonian: Riski vastsündinule ei saa välistada.
English: The combination was generally well tolerated.
Estonian: Kombinatsioon oli üldiselt hästi talutav.
English: (see section 4.3).
Estonian: (Vt lõik 4.4.)
English: This combination should be used with caution.
Estonian: Seda kombinatsiooni peab kasutama ettevaatusega.
English: 10000 Zagreb, Croatia
Estonian: 10000 Zagreb, Horvaatia
English: ** Based on historical comparison
Estonian: ** varasema võrdluse põhjal
English: See below and section 5.3.
Estonian: Vt all ja lõik 5.3.
English: Triacetin 3
Estonian: Triatsetiin 3
English: It is used by adults, adolescents and children 3 years of age and older.
Estonian: Seda kasutatakse täiskasvanutel, noorukitel ja lastel vanuses 3 aastat ja enam.
English: - It is recommended that the tablet be swallowed whole with water.
Estonian: - Soovitatav on neelata alla tablett tervelt koos veega.
English: (mechanism)
Estonian: (mehhanism)
English: (UDP-G induction)
Estonian: (UDP-G indutseerimine)
English: - unexplained feelings of distress not associated with hallucinations, but it may be difficult to think clearly or sensibly - suicide
Estonian: - seletamatu ahastustunne, mis ei ole seotud hallutsinatsioonidega, kuid siis võib olla keeruline mõelda selgelt või mõistlikult - enesetapp
English: Date of first authorisation: 9 January 2012 Date of latest renewal: 9 September 2016
Estonian: Müügiloa esmase väljastamise kuupäev: 09/01/2012 Müügiloa viimase uuendamise kuupäev: 09/09/2016
English: Teva B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
Estonian: Teva B.V., Swensweg 5, 2031GA Haarlem, Holland
English: Component of a multipack, can't be sold separately.
Estonian: Hulgipakendi osa ei või müüa eraldi.
English: Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines.
Estonian: Teatage oma arstile, apteekrile või meditsiiniõele, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: Gender, race, elderly
Estonian: Sugu, rass, eakad
English: (PLIVA Croatia Ltd.), Prilaz baruna Filipovića 25, 10000 Zagreb, Croatia
Estonian: Pliva Croatia Ltd, Prilaz baruna Filipovića 25, 10000 Zagreb, Horvaatia
English: Study ACTG 364 48 weeks
Estonian: Uuring ACTG 48 nädalat
English: Efavirenz concentrations not measured, no effect is expected.
Estonian: Efavirensi kontsentratsiooni ei ole mõõdetud, efekti ei ole oodata.
English: Tell your doctor if you notice any of the following side effects: Very common (affects more than 1 user in 10)
Estonian: Informeerige oma arsti sellest, kui te märkate mõnda järgnevalt loetletud kõrvaltoimeid: Väga sage (tekib rohkem kui ühel kasutajal 10-st)
English: - Efavirenz Teva must be taken every day.
Estonian: - Efavirenz Teva't tuleb võtta iga päev.
English: (CYP3A induction - effect on boceprevir) *0-8 hours
Estonian: (CYP3A indutseerimine - toime avaldub botsepreviiril) * 0…8 tundi
English: Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud blistril ja karbil pärast "EXP“.
English: ---, not performed.
Estonian: ---, ei ole uuritud.